| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Lian Duan, Huijuan Zhu, Bing Xing, Feng G. Prolonged preoperative treatment of acromegaly with Somatostatin analogs may improve surgical outcome in patients with invasive pituitary macroadenoma (Knosp grades 1-3): a retrospective cohort study conducted at a single center. BMC endocrine disorders. vol 17. issue 1. 2018-06-06. PMID:28874187. |
this study aimed to investigate preoperative somatostatin analogs (ssas) treatment on the surgical outcome in patients with acromegaly. |
2018-06-06 |
2023-08-13 |
Not clear |
| Ammar Muhammad, Aart J van der Lely, Patric J D Delhanty, Alof H G Dallenga, Iain K Haitsma, Joseph A M J L Janssen, Sebastian J C M M Negger. Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study). The Journal of clinical endocrinology and metabolism. vol 103. issue 2. 2018-05-25. PMID:29155991. |
efficacy and safety of switching to pasireotide in patients with acromegaly controlled with pegvisomant and first-generation somatostatin analogues (pape study). |
2018-05-25 |
2023-08-13 |
Not clear |
| Ammar Muhammad, Aart J van der Lely, Patric J D Delhanty, Alof H G Dallenga, Iain K Haitsma, Joseph A M J L Janssen, Sebastian J C M M Negger. Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study). The Journal of clinical endocrinology and metabolism. vol 103. issue 2. 2018-05-25. PMID:29155991. |
to assess the efficacy and safety of pasireotide long-acting release (pas-lar) alone or in combination with pegvisomant by switching patients with acromegaly who were well controlled with long-acting somatostatin analogues (la-ssas) and pegvisomant to pas-lar with or without pegvisomant. |
2018-05-25 |
2023-08-13 |
Not clear |
| R Dineen, P M Stewart, M Sherloc. Acromegaly. QJM : monthly journal of the Association of Physicians. vol 110. issue 7. 2018-05-22. PMID:26873451. |
the therapeutic options for acromegaly include surgery, medical therapies (such as dopamine agonists, somatostatin receptor agonists and the gh receptor antagonist pegvisomant) and radiotherapy. |
2018-05-22 |
2023-08-13 |
Not clear |
| Sarinj Fattah, David J Brayde. Progress in the formulation and delivery of somatostatin analogs for acromegaly. Therapeutic delivery. vol 8. issue 10. 2018-05-09. PMID:28944744. |
progress in the formulation and delivery of somatostatin analogs for acromegaly. |
2018-05-09 |
2023-08-13 |
Not clear |
| Massimo Terzolo, Giuseppe Reimondo, Paola Berchialla, Emanuele Ferrante, Elena Malchiodi, Laura De Marinis, Rosario Pivonello, Silvia Grottoli, Marco Losa, Salvatore Cannavo, Diego Ferone, Marcella Montini, Marta Bondanelli, Ernesto De Menis, Chiara Martini, Efisio Puxeddu, Antonino Velardo, Alessandro Peri, Marco Faustini-Fustini, Patrizia Tita, Francesca Pigliaru, Giulia Peraga, Giorgio Borretta, Carla Scaroni, Nicoletta Bazzoni, Antonio Bianchi, Alessandro Berton, Andreea Liliana Serban, Roberto Baldelli, Letizia Maria Fatti, Annamaria Colao, Maura Arosi. Acromegaly is associated with increased cancer risk: a survey in Italy. Endocrine-related cancer. vol 24. issue 9. 2018-04-30. PMID:28710115. |
the aim of the present study was to assess the standardized incidence ratios (sirs) of different types of cancer in acromegaly on a large series of acromegalic patients managed in the somatostatin analogs era. |
2018-04-30 |
2023-08-13 |
Not clear |
| Stacy S Tse, Troy Kis. Octreotide-Associated Neutropenia. Pharmacotherapy. vol 37. issue 6. 2018-04-03. PMID:28488730. |
octreotide is a somatostatin analog that has been used to treat variceal bleeding, acromegaly, and severe diarrhea associated with metastatic tumors, and to reduce symptoms in the setting of malignant bowel obstruction and pseudoobstruction. |
2018-04-03 |
2023-08-13 |
Not clear |
| Kiyoe Kurahashi, Itsuro Endo, Takeshi Kondo, Kana Morimoto, Sumiko Yoshida, Akio Kuroda, Ken-Ichi Aihara, Munehide Matsuhisa, Kohei Nakajima, Yoshifumi Mizobuchi, Shinji Nagahiro, Masahiro Abe, Seiji Fukumot. Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review. Internal medicine (Tokyo, Japan). vol 56. issue 18. 2018-04-02. PMID:28824054. |
a literature review of the predictors for tumor shrinkage after the administration of somatostatin analogues in patients with acromegaly is also discussed in relation to this case. |
2018-04-02 |
2023-08-13 |
Not clear |
| Mai Christiansen Arlien-Søborg, Christian Trolle, Elin Alvarson, Amanda Bæk, Jakob Dal, Jens Otto Lunde Jørgense. Biochemical assessment of disease control in acromegaly: reappraisal of the glucose suppression test in somatostatin analogue (SA) treated patients. Endocrine. vol 56. issue 3. 2018-03-26. PMID:28260207. |
biochemical assessment of disease control in acromegaly: reappraisal of the glucose suppression test in somatostatin analogue (sa) treated patients. |
2018-03-26 |
2023-08-13 |
Not clear |
| Mai Christiansen Arlien-Søborg, Christian Trolle, Elin Alvarson, Amanda Bæk, Jakob Dal, Jens Otto Lunde Jørgense. Biochemical assessment of disease control in acromegaly: reappraisal of the glucose suppression test in somatostatin analogue (SA) treated patients. Endocrine. vol 56. issue 3. 2018-03-26. PMID:28260207. |
it is recommended not to measure growth hormone during oral glucose suppression (oral glucose tolerance test) during somatostatin analog treatment in acromegaly. |
2018-03-26 |
2023-08-13 |
Not clear |
| Ilan Shimon, Wolfgang Saeger, Luiz Eduardo Wildemberg, Monica R Gadelh. Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control. Hormones (Athens, Greece). vol 16. issue 1. 2018-03-08. PMID:28500831. |
to present two female patients with acromegaly inadequately controlled with long-acting octreotide who were subsequently treated with the multireceptor-targeted somatostatin analogue pasireotide that over-suppressed igf-1 levels. |
2018-03-08 |
2023-08-13 |
Not clear |
| Ming Shen, Qilin Zhang, Wenjuan Liu, Meng Wang, Jingjing Zhu, Zengyi Ma, Wenqiang He, Shiqi Li, Xuefei Shou, Yiming Li, Zhaoyun Zhang, Hongying Ye, Min He, Bin Lu, Zhenwei Yao, Yun Lu, Nidan Qiao, Zhao Ye, Yichao Zhang, Yeping Yang, Yao Zhao, Yongfei Wan. Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly. Neuroradiology. vol 58. issue 11. 2018-02-05. PMID:27516099. |
predictive value of t2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly. |
2018-02-05 |
2023-08-13 |
Not clear |
| Ming Shen, Qilin Zhang, Wenjuan Liu, Meng Wang, Jingjing Zhu, Zengyi Ma, Wenqiang He, Shiqi Li, Xuefei Shou, Yiming Li, Zhaoyun Zhang, Hongying Ye, Min He, Bin Lu, Zhenwei Yao, Yun Lu, Nidan Qiao, Zhao Ye, Yichao Zhang, Yeping Yang, Yao Zhao, Yongfei Wan. Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly. Neuroradiology. vol 58. issue 11. 2018-02-05. PMID:27516099. |
here, we quantitatively evaluated the predictive value of relative signal intensity (rsi) on t1- and t2-weighted magnetic resonance imaging (mri) for the short-term efficacy (3 months) of ssa therapy in patients with active acromegaly and assessed the correlation between mri rsi and expression of somatostatin receptors (sstr). |
2018-02-05 |
2023-08-13 |
Not clear |
| Iulia Potorac, Patrick Petrossians, Adrian F Daly, Orsalia Alexopoulou, Sophie Borot, Mona Sahnoun-Fathallah, Frederic Castinetti, France Devuyst, Marie-Lise Jaffrain-Rea, Claire Briet, Florina Luca, Marion Lapoirie, Flavius Zoicas, Isabelle Simoneau, Alpha M Diallo, Ammar Muhammad, Fahrettin Kelestimur, Elena Nazzari, Rogelio Garcia Centeno, Susan M Webb, Marie-Laure Nunes, Vaclav Hana, Véronique Pascal-Vigneron, Irena Ilovayskaya, Farida Nasybullina, Samia Achir, Diego Ferone, Sebastian J C M M Neggers, Brigitte Delemer, Jean-Michel Petit, Christof Schöfl, Gerald Raverot, Bernard Goichot, Patrice Rodien, Bernard Corvilain, Thierry Brue, Franck Schillo, Luaba Tshibanda, Dominique Maiter, Jean-François Bonneville, Albert Becker. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocrine-related cancer. vol 23. issue 11. 2017-12-29. PMID:27649724. |
t2-weighted mri signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. |
2017-12-29 |
2023-08-13 |
Not clear |
| Iulia Potorac, Patrick Petrossians, Adrian F Daly, Orsalia Alexopoulou, Sophie Borot, Mona Sahnoun-Fathallah, Frederic Castinetti, France Devuyst, Marie-Lise Jaffrain-Rea, Claire Briet, Florina Luca, Marion Lapoirie, Flavius Zoicas, Isabelle Simoneau, Alpha M Diallo, Ammar Muhammad, Fahrettin Kelestimur, Elena Nazzari, Rogelio Garcia Centeno, Susan M Webb, Marie-Laure Nunes, Vaclav Hana, Véronique Pascal-Vigneron, Irena Ilovayskaya, Farida Nasybullina, Samia Achir, Diego Ferone, Sebastian J C M M Neggers, Brigitte Delemer, Jean-Michel Petit, Christof Schöfl, Gerald Raverot, Bernard Goichot, Patrice Rodien, Bernard Corvilain, Thierry Brue, Franck Schillo, Luaba Tshibanda, Dominique Maiter, Jean-François Bonneville, Albert Becker. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocrine-related cancer. vol 23. issue 11. 2017-12-29. PMID:27649724. |
we conducted the current multicenter study in a large population of patients with acromegaly to analyze the relationship between t2-weighted signal intensity on diagnostic mri and hormonal and tumoral responses to somatostatin analogs (ssa) as primary monotherapy. |
2017-12-29 |
2023-08-13 |
Not clear |
| Kjell Öberg, Steven W J Lambert. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Endocrine-related cancer. vol 23. issue 12. 2017-12-29. PMID:27697899. |
somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. |
2017-12-29 |
2023-08-13 |
Not clear |
| Kjell Öberg, Steven W J Lambert. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Endocrine-related cancer. vol 23. issue 12. 2017-12-29. PMID:27697899. |
current medical therapy for the treatment of acromegaly and gep-net involves the administration of somatostatin analogues that effectively suppress excess hormone secretion. |
2017-12-29 |
2023-08-13 |
Not clear |
| Kjell Öberg, Steven W J Lambert. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Endocrine-related cancer. vol 23. issue 12. 2017-12-29. PMID:27697899. |
more recently, pasireotide (signifor), a next-generation multireceptor-targeted somatostatin analogue, has emerged as an alternative therapeutic option for the treatment of acromegaly. |
2017-12-29 |
2023-08-13 |
Not clear |
| Jakob Dal, Marianne Klose, Ansgar Heck, Marianne Andersen, Caroline Kistorp, Eigil H Nielsen, Jens Bollerslev, Ulla Feldt-Rasmussen, Jens O L Jørgense. Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study. European journal of endocrinology. vol 178. issue 1. 2017-11-27. PMID:28993415. |
targeting either gh or igf-i during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study. |
2017-11-27 |
2023-08-13 |
Not clear |
| Michelle H Gurel, Yi Han, Andrea L Stevens, Aaron Furtado, David Co. Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis. BMC pharmacology & toxicology. vol 18. issue 1. 2017-10-24. PMID:28372573. |
treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis. |
2017-10-24 |
2023-08-13 |
Not clear |